Oxford-AstraZeneca's COVID-19 vaccine is shockingly cheap

An interim trial analysis for Oxford-AstraZeneca's COVID-19 vaccine found the candidate's average efficacy to be 70 percent. While considered encouraging, it falls short of the rates shown by Pfizer/BioNTech and Moderna, whose vaccines appear to be more than 90 percent effective.

Still, the Oxford-AstraZeneca candidate has a few key advantages — it can be stored at regular refrigerators temperatures for a long period of time, and it's much cheaper than the other candidates, which means it could be particularly crucial for developing nations and rural communities around the world.

The vaccine costs just $3 to $4 per dose. In comparison, the Pfizer and Moderna candidates cost around $20 and $30, respectively. AstraZeneca has also made a "no-profit" pledge, and the more-established technology used by Oxford means it will be easier to mass produce cheaply, BBC News notes. Read more at BBC and The Financial Times. Tim O'Donnell

The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up